{
    "clinical_study": {
        "@rank": "1463", 
        "arm_group": [
            {
                "arm_group_label": "Experimental  (EF) 1", 
                "arm_group_type": "Experimental", 
                "description": "For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1"
            }, 
            {
                "arm_group_label": "Standard Formula", 
                "arm_group_type": "Active Comparator", 
                "description": "For 8 weeks, infants will consume ad libitum per day. S-26 Gold"
            }, 
            {
                "arm_group_label": "Experimental 2 (EF2) S-26 Gold", 
                "arm_group_type": "Experimental", 
                "description": "For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2"
            }, 
            {
                "arm_group_label": "Human milk (HM)", 
                "arm_group_type": "Other", 
                "description": "For 8 weeks, infants will consume ad libitum per day. Human Milk"
            }, 
            {
                "arm_group_label": "Experimental formula (EF) 3", 
                "arm_group_type": "Experimental", 
                "description": "For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary efficacy objective was to determine and compare stool composition (stool soap\n      and non-soap fatty acids, total fatty acids, minerals, and other stool constituents) among\n      the feeding groups."
        }, 
        "brief_title": "Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas", 
        "completion_date": {
            "#text": "August 2009", 
            "@type": "Actual"
        }, 
        "condition": "Stool Composition", 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the effects of term infant formula containing high\n      2-palmitic vegetable oil on stool composition and characteristics and to investigate the\n      effect of both high 2-palmitic vegetable oil and oligofructose in infant formula on stool\n      softness and bacteria.  Because some studies demonstrate the benefit of high concentrations\n      of a non-digestible carbohydrate in the formula, we will study 2 concentrations of added\n      oligofructose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy, term (no less than 37 weeks, 0 days and no greater than 42 weeks, 0 days)\n             singleton infants, between 7 days and 14 day post natal age\n\n          2. Weight for age \u22655th percentile according to Filipino growth tables/charts.\n\n          3. HM infants were exclusively consuming and tolerating HM\n\n          4. Mother must have made the decision to continue to exclusively breastfeed.\n\n          5. Formula-fed infants were exclusively consuming and tolerating a cow's milk infant\n             formula\n\n          6. Parent/guardian must have previously made the decision to continue to exclusively\n             formula feed\n\n        Exclusion Criteria:\n\n          1. Infants who are receiving any amount of supplemental HM with infant formula feeding\n             or visa versa\n\n          2. Infants who are receiving any infant formula containing pro- or prebiotics\n\n          3. Family history of siblings with documented cow's milk protein intolerance/allergy\n\n          4. Conditions requiring infant feedings other than those specified in the protocol\n\n          5. Major congenital malformations (e.g. cleft palate, hemangiomas, extremity\n             malformation)\n\n          6. Suspected or documented systemic or congenital infections (e.g. human\n             immunodeficiency virus, cytomegalovirus)\n\n          7. Evidence of significant cardiac, respiratory, endocrinologic, hematologic,\n             gastrointestinal, or other systemic diseases\n\n          8. Infants who have received any experimental treatment, participated in any other\n             clinical trial, or received any other investigational intervention unrelated to this\n             trial, prior to enrollment\n\n          9. Infants of any ancillary personnel connected with the study or the infants of first\n             and second-degree relatives (parents, brothers, sisters, children, or grandchildren)\n             of ancillary personnel\n\n         10. Presently receiving or have received any medication(s) which are known or suspected\n             to affect fat digestion, absorption and/or metabolism (e.g., pancreatic enzymes), any\n             vitamin and/or mineral supplements which contain calcium, all antibiotics and\n             antifungal medications (except topical), suppositories, bismuth-containing\n             medications, herbal supplements, or medications which may neutralize or suppress\n             gastric acid secretion\n\n         11. HM-fed infants whose mothers are presently receiving or have received any antibiotics\n             or antifungal medications (except topical), post partum"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "14 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "375", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861600", 
            "org_study_id": "9055A1-3001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Formula", 
                "description": "(13.4 g/L protein) with 100% Fat Blend A", 
                "intervention_name": "S-26 Gold", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Experimental  (EF) 1", 
                "description": "(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend", 
                "intervention_name": "S-26 Gold EF1", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Experimental 2 (EF2) S-26 Gold", 
                "description": "(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose", 
                "intervention_name": "S-26 Gold EF2", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Experimental formula (EF) 3", 
                "description": "(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose", 
                "intervention_name": "S-26 Gold EF3", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Human milk (HM)", 
                "description": "Human Milk", 
                "intervention_name": "Human Milk", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Stool composition", 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Metro Manila", 
                    "country": "Philippines", 
                    "state": "Alabang", 
                    "zip": "1780"
                }, 
                "name": "Asian Hospital and Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Philippines"
        }, 
        "number_of_arms": "5", 
        "official_title": "Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas", 
        "other_outcome": [
            {
                "description": "evaluation of adverse events", 
                "measure": "Safety evaluation", 
                "safety_issue": "Yes", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Anthropometric measurements", 
                "measure": "Growth evaluation", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "JRF Health Center Complex, Muntinlupa City, Philippines", 
            "last_name": "Maria Rosario Zeta Capeding, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Philippines : Food and Drug Administration", 
                "Philippines: Philippine Council for Health Research and Development", 
                "Philippines: Bureau of Food and Drugs", 
                "Philippines: Department of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "stool composition: stool soap and non-soap fatty acids, total fatty acids, minerals, and other stool constituents", 
            "measure": "Stool Composition in Healthy Term Infants Fed Human Milk or Infant Formulas", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Determinations of fecal flora as well as fecal pH, sIgA concentrations and SCFA concentrations in a subset of subjects.", 
            "measure": "Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Nestl\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nestl\u00e9", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}